Non-Alcoholic Fatty Liver Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Boys and girls between 12 and 18 years old who are obese and have been diagnosed with a liver condition called NAFLD (non-alcoholic fatty liver disease)
- Participants should be at a mid-to-later stage of puberty (confirm with trial site)
Who may not be able to join:
- Young people who have another known liver disease (such as Wilson disease, viral hepatitis, or certain metabolic conditions) that can also cause liver problems
- Young people who have been diagnosed with Type 2 Diabetes, or who currently take insulin
- Young people taking certain medications known to affect the liver, such as methotrexate, corticosteroids, valproic acid, or statins
- Young people who have a more advanced form of liver scarring called bridging fibrosis (confirm with trial site)
- Young people with a known history of significant smoking or alcohol use
- Young people who are currently on an active weight loss program or who have had weight loss (bariatric) surgery
- Anyone who has a cardiac pacemaker or metal pins in their body, as these are not safe for the MRI/MRS scans used in this study
- Anyone who is pregnant, as this is not safe for the MRI/MRS scans used in this study — all females who could potentially be pregnant will be asked to take a urine pregnancy test before scanning
- Any child with significant developmental delays or other serious health conditions that would make it difficult for them to take part in the study activities
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Diana R Mager, PhD RD, University of Alberta
Phone: 780-492-7687
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in 31P spectra from abdominal MRI scans in response to dietary intervention.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.